Regensburg, Germany
Lophius Biosciences GmbH, founded in 2008 and headquartered in Germany, is a rising player in the Biotechnology and Health Care industries. The company aims to revolutionize treatment and management of infectious diseases with its pioneering molecular diagnostic solutions.
Lophius Biosciences is tackling the global TB epidemic by developing a proprietary blood-based multi-marker solution that provides enhanced detection compared to existing methods. This innovation could differentiate between active TB and latent TB infections, addressing a critical clinical challenge.
Further diversifying its portfolio, Lophius is commercializing a CE marked diagnostic kit that offers personalized CMV disease risk assessments for transplant patients, underlining its focus on individualized patient care.
The company's last investment was an acquisition by MIKROGEN GmbH on 01 March 2021, signaling strong interest and support from established industry players in its transformative healthcare solutions.
